UC San Diego adds 4 patients to Neuralstem's neural stem cell study for spinal cord injury: 6 takeaways

Spine

Germantown, Md.-based Neuralstem is involved in a Phase 1 human clinical trial testing the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair chronic spinal cord injury.

A biopharmaceutical company, Neuralstem develops nervous system therapies derived from neural stem cell technology.

 

Here are six takeaways:

 

1. NSI-566 represents the company's lead stem cell therapy candidate.

 

2. University of California San Diego serves as the study site, and just added a new cohort of four patients.

 

3. The four new patients all have AIS-A complete, quadriplegic, cervical injuries involving C5-C7 cord.

 

4. The patients suffered the injury one to two years before undergoing stem cell treatment.

 

5. The treatment involves six injections of NSI-566 into the spinal cord's affected area.

 

6. UCSD researchers are analyzing long-term safety data from the study's first cohort on chronic complete thoracic injuries.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers